"FDA Grants Breakthrough Designation to Single Dose LSD Therapy for Anxiety"
TL;DR Summary
A new study conducted by biopharmaceutical company MindMed has found that a single dose of MM120, a form of LSD, can provide lasting relief to patients suffering from generalized anxiety disorder (GAD), with a 48% rate of remission after 12 weeks and about 65% of patients seeing improvements within three months. The drug will need to go through the standard FDA approval process and will soon enter phase III trials.
- Single dose of LSD can cut anxiety in half within weeks: 'Breakthrough' study New York Post
- Psychedelic news: The government finally fast-tracked LSD as an anxiety treatment Fast Company
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder Yahoo Finance
- FDA designates LSD-based drug as possible breakthrough treatment for anxiety UPI News
- MindMed's stock soars 58% after FDA grants breakthrough designation to LSD therapy for a form of anxiety Morningstar
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
86%
497 → 70 words
Want the full story? Read the original article
Read on New York Post